vimarsana.com

Page 6 - Pascal Touchon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Experimental cell therapy ATA188 fails to show benefits in MS trial

Experimental cell therapy ATA188 fails to show benefits in MS trial
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and.

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal.

Why Atara Biotherapeutics (ATRA) Shares Are Plummeting Today - Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS) did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disabi

ATARA Biotherapeutics (ATRA) Reports Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188

ATARA Biotherapeutics (ATRA) Reports Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.